Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.
Simple Summary: Pancreatic cancer treatment often requires coordinated systemic therapy, but national data rarely show how specialist-team availability relates to treatment processes. We used nationwide data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) to compare facilities...
| Publicado en: | Current Oncology Vol. 33; no. 7; pp. 393 - 408 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195807425&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195807425 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jul2026 vid: 33 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 195807425 10.3390/curroncol33070393 195807425 ppf: 393 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis. aug: au: Kajiura, Shinya Satake, Hironaga Nakamura, Naohiko Hayashi, Ryuji affil: Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama 930-0194, Japan sug: ab: Simple Summary: Pancreatic cancer treatment often requires coordinated systemic therapy, but national data rarely show how specialist-team availability relates to treatment processes. We used nationwide data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) to compare facilities with 0–1 versus ≥2 registry-listed Japanese Society of Medical Oncology (JSMO) specialists. The analysis focused on time from systemic therapy start to recorded first-line treatment end. Among 14,568 patients at 261 facilities, median recorded first-line treatment-process duration was 5.7 months at facilities with 0–1 specialists and 6.4 months at facilities with ≥2 specialists; the association persisted after clinical and facility adjustment. Supportive overall survival did not support a corresponding survival advantage. These results show a facility-level association in registry-derived treatment-process data, not direct specialist involvement, treatment efficacy, facility quality, causality, or survival benefit. Chemotherapy-specific national database elements are needed for direct evaluation. Facility-level availability of Japanese Society of Medical Oncology (JSMO) specialists may influence care processes, but national cancer genomic medicine data rarely capture patient-level specialist involvement. We conducted a nationwide retrospective analysis of pancreatic cancer cases in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT). The primary exposure was facility-level registry-listed JSMO specialist count (0–1 vs. ≥2 specialists), with ≥2 interpreted as a proxy for minimum plural specialist-team availability. The primary endpoint was time from systemic therapy start to recorded first-line treatment end. The primary cohort included 14,568 patients at 261 facilities. Median recorded first-line treatment-process duration was 5.7 months in the 0–1 specialist group and 6.4 months in the ≥2 specialist group. In the clinical plus facility-adjusted Cox model, ≥2 specialist availability was associated with a lower hazard of recorded first-line treatment end (HR 0.895, 95% CI 0.810–0.988; p = 0.028). Supportive overall survival findings did not indicate a survival advantage, reinforcing the operational nature of the primary endpoint. These findings indicate a facility-level association with an operational treatment-process endpoint, not patient-level specialist involvement, treatment efficacy, survival benefit, facility ranking, or causality. Chemotherapy-specific national database elements are needed to evaluate specialist contribution directly. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|